Organon & Co. (NYSE:OGN) Shares Bought by Advisors Asset Management Inc.

Advisors Asset Management Inc. boosted its holdings in Organon & Co. (NYSE:OGN - Free Report) by 6.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 706,429 shares of the company's stock after purchasing an additional 45,865 shares during the period. Advisors Asset Management Inc. owned about 0.27% of Organon & Co. worth $10,540,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of OGN. Crossmark Global Holdings Inc. lifted its holdings in Organon & Co. by 43.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 20,157 shares of the company's stock worth $385,000 after purchasing an additional 6,096 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Organon & Co. by 127.3% during the 3rd quarter. Victory Capital Management Inc. now owns 183,298 shares of the company's stock valued at $3,506,000 after acquiring an additional 102,663 shares during the period. KBC Group NV boosted its holdings in Organon & Co. by 19.5% during the 3rd quarter. KBC Group NV now owns 7,744 shares of the company's stock valued at $148,000 after acquiring an additional 1,263 shares during the period. Natixis Advisors LLC lifted its holdings in Organon & Co. by 7.9% in the 3rd quarter. Natixis Advisors LLC now owns 48,215 shares of the company's stock worth $922,000 after buying an additional 3,520 shares during the period. Finally, Aljian Capital Management LLC purchased a new stake in Organon & Co. in the 3rd quarter worth approximately $196,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

Remove Ads

Organon & Co. Stock Performance

Shares of NYSE OGN traded down $0.27 during mid-day trading on Friday, hitting $15.33. The stock had a trading volume of 20,289,041 shares, compared to its average volume of 2,403,290. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company has a 50 day moving average of $15.44 and a two-hundred day moving average of $16.49. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The firm has a market cap of $3.95 billion, a PE ratio of 4.60, a PEG ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Research analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a dividend of $0.28 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.31%. Organon & Co.'s dividend payout ratio is currently 33.63%.

Analyst Ratings Changes

A number of research analysts recently weighed in on OGN shares. TD Cowen raised Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Morgan Stanley lowered their target price on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday, February 14th. Finally, Barclays lowered their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $20.80.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.